Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Moodys
Dow
Johnson and Johnson
McKinsey

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for FG-4592

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug FG-4592?

FG-4592 is an investigational drug.

There have been 25 clinical trials for FG-4592. The most recent clinical trial was a Phase 2 trial, which was initiated on June 11th 2019.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Europe B.V., and AstraZeneca.

There are twenty-eight US patents protecting this investigational drug and one hundred and ninety-four international patents.

Recent Clinical Trials for FG-4592
TitleSponsorPhase
Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsSecond Xiangya Hospital of Central South UniversityPhase 4
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaAstellas Pharma IncPhase 2
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaAstraZenecaPhase 2

See all FG-4592 clinical trials

Clinical Trial Summary for FG-4592

Top disease conditions for FG-4592
Top clinical trial sponsors for FG-4592

See all FG-4592 clinical trials

US Patents for FG-4592

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
FG-4592   Start Trial Nitrogen-containing heteroaryl compounds and methods of use thereof FibroGen, Inc. (San Francisco, CA)   Start Trial
FG-4592   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
FG-4592   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Moodys
Harvard Business School
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.